MX2021010451A - Firma proteica para la diagnosis de cáncer colorrectal y/o etapa pre cancerosa del mismo. - Google Patents

Firma proteica para la diagnosis de cáncer colorrectal y/o etapa pre cancerosa del mismo.

Info

Publication number
MX2021010451A
MX2021010451A MX2021010451A MX2021010451A MX2021010451A MX 2021010451 A MX2021010451 A MX 2021010451A MX 2021010451 A MX2021010451 A MX 2021010451A MX 2021010451 A MX2021010451 A MX 2021010451A MX 2021010451 A MX2021010451 A MX 2021010451A
Authority
MX
Mexico
Prior art keywords
diagnosis
colorectal cancer
protein signature
cancerous stage
cancerous
Prior art date
Application number
MX2021010451A
Other languages
English (en)
Spanish (es)
Inventor
Rodríguez Ana Carmen Martín
Palacios Rosa Pérez
Arranz Rocío Arroyo
Original Assignee
Advanced Marker Discovery S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Marker Discovery S L filed Critical Advanced Marker Discovery S L
Publication of MX2021010451A publication Critical patent/MX2021010451A/es

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52Assays involving cytokines
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/56Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
MX2021010451A 2019-03-01 2020-02-28 Firma proteica para la diagnosis de cáncer colorrectal y/o etapa pre cancerosa del mismo. MX2021010451A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19382157 2019-03-01
EP19382156 2019-03-01
PCT/EP2020/055277 WO2020178172A1 (en) 2019-03-01 2020-02-28 Protein signature for the diagnosis of colorectal cancer and/or pre-cancerous stage thereof

Publications (1)

Publication Number Publication Date
MX2021010451A true MX2021010451A (es) 2021-12-10

Family

ID=69631636

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021010451A MX2021010451A (es) 2019-03-01 2020-02-28 Firma proteica para la diagnosis de cáncer colorrectal y/o etapa pre cancerosa del mismo.

Country Status (10)

Country Link
US (1) US20220276249A1 (https=)
EP (1) EP3931571B1 (https=)
JP (2) JP2022522803A (https=)
KR (1) KR102769007B1 (https=)
CN (1) CN113785199B (https=)
AU (1) AU2020230963B2 (https=)
CA (1) CA3131729A1 (https=)
ES (1) ES2952139T3 (https=)
MX (1) MX2021010451A (https=)
WO (1) WO2020178172A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2952139T3 (es) * 2019-03-01 2023-10-27 Advanced Marker Discovery S L Firma proteica para el diagnóstico de cáncer colorrectal y/o etapa precancerosa del mismo
WO2021185982A1 (en) * 2020-03-19 2021-09-23 Advanced Marker Discovery S.l. Protein signature for screening general population for colorectal cancer and/or pre-cancerous stage thereof
CA3202255A1 (en) 2020-12-21 2022-06-30 Hayley WARSINSKE Markers for the early detection of colon cell proliferative disorders
KR102900859B1 (ko) * 2021-12-31 2025-12-17 주식회사 이노제닉스 대장암 및 대장 용종 또는 진행 선종의 선별 방법 및 그 응용

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602005014386D1 (de) * 2004-12-23 2009-06-18 Roche Diagnostics Gmbh Verwendung von cyfra 21-1 und osteopontin als marker für kolorektalkarzinome
CN101896817A (zh) * 2007-12-10 2010-11-24 霍夫曼-拉罗奇有限公司 用于结直肠癌的标记物组
CN103140760B (zh) * 2010-07-14 2016-01-27 联邦科学与工业研究组织 结肠直肠癌的诊断
US20140220006A1 (en) * 2013-02-01 2014-08-07 Meso Scale Technologies, Llc Lung cancer biomarkers
US20160291025A1 (en) * 2013-09-18 2016-10-06 Adelaide Research & Innovation Pty Ltd Autoantibody biomarkers of ovarian cancer
JP6339399B2 (ja) * 2014-03-28 2018-06-06 学校法人北里研究所 卵巣明細胞腺癌細胞の検出方法、卵巣明細胞腺癌診断薬、卵巣明細胞腺癌診断用プライマー、卵巣明細胞腺癌診断用キット、及び卵巣明細胞腺癌診断用プローブ
EP3073268A1 (en) * 2015-03-27 2016-09-28 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Biomarker panel for diagnosing cancer
JP2018136122A (ja) * 2015-05-29 2018-08-30 国立研究開発法人国立がん研究センター 膵がんを診断するための血漿バイオマーカーパネル
US20180160885A1 (en) * 2016-12-13 2018-06-14 Prosper Abitbol Endoscopy based medical devices, methods, and innovations
KR102018205B1 (ko) * 2017-07-24 2019-09-05 (주) 바이오인프라생명과학 대장암 진단용 조성물 및 상기 조성물을 이용한 대장암 진단 방법
US10968583B2 (en) * 2017-07-26 2021-04-06 David E. Lambert Reflective road marker
ES2952139T3 (es) * 2019-03-01 2023-10-27 Advanced Marker Discovery S L Firma proteica para el diagnóstico de cáncer colorrectal y/o etapa precancerosa del mismo
WO2021185982A1 (en) * 2020-03-19 2021-09-23 Advanced Marker Discovery S.l. Protein signature for screening general population for colorectal cancer and/or pre-cancerous stage thereof

Also Published As

Publication number Publication date
US20220276249A1 (en) 2022-09-01
AU2020230963A1 (en) 2021-09-30
CN113785199A (zh) 2021-12-10
EP3931571B1 (en) 2023-06-07
JP2022522803A (ja) 2022-04-20
BR112021017248A2 (pt) 2021-11-09
EP3931571C0 (en) 2023-06-07
KR102769007B1 (ko) 2025-02-14
ES2952139T3 (es) 2023-10-27
CA3131729A1 (en) 2020-09-10
JP2025038186A (ja) 2025-03-18
WO2020178172A1 (en) 2020-09-10
EP3931571A1 (en) 2022-01-05
KR20210134946A (ko) 2021-11-11
AU2020230963B2 (en) 2026-03-12
CN113785199B (zh) 2024-02-09

Similar Documents

Publication Publication Date Title
CL2020003071A1 (es) Proteínas de unión multiespecíficas y mejoras con estas
CY1124106T1 (el) Συνθεσεις μεταφορεα-αντισωματος και μεθοδοι παρασκευης και χρησης αυτων
MX2020009568A (es) Anticuerpos que se unen a cd39 y sus usos.
CO2021001912A2 (es) Composiciones anti-cd112r y métodos
MX2021014286A (es) Proteinas multiespecificas.
MX2021010451A (es) Firma proteica para la diagnosis de cáncer colorrectal y/o etapa pre cancerosa del mismo.
CY1123290T1 (el) Ενωσεις και μεθοδοι χρησης
SA519401522B1 (ar) Lag-3 أجـسـام مـضـادة لـ وتـركـيـبـات
MX2018009581A (es) Inmunoglobulina con fabs en tandem y sus usos.
CL2019000061A1 (es) Anticuerpo para anti-claudin 18a2 y su utilización.
EP4219559A3 (en) Antibodies for lilrb2
CU20160101A7 (es) Inmunoglobulina con fab en tándem
DOP2016000153A (es) Anticuerpos y fragmentos anti-vista
EA201690617A1 (ru) Комбинирование anti-lag-3-антител и анти-pd-1-антител для лечения опухолей
GT201700286A (es) Modulación y tratamiento inmunes de tumores sólidos con anticuerpos que se unen específicamente a cd38
EA201991369A1 (ru) Модифицированные направляющие рнк
CL2016002017A1 (es) Inhibición dirigida del factor de crecimiento transformador b (tgfb).
CO2017004516A2 (es) Anticuerpos anti-ox40 humanizados
TR2021016542A2 (tr) Plazma bazlı filmler ve bunları üretme ve kullanma usulleri.
MX391249B (es) Anticuerpos anti-muc16 y sus usos.
MX2019011148A (es) Metodos de tratamiento.
ECSP17011657A (es) Conjugados de fármacos con anticuerpos anti-cdh6
EA201790413A1 (ru) Антитела против tigit
AR090973A1 (es) Anticuerpos utiles para el diagnostico del cancer
UY34656A (es) Polimorfos de (s)?2?(1?(9h?purin?6?ilamino)propil)?5?fluor?3?fenilquinazolin?4(3h)?ona, composición y método de preparación